Group items tagged

Autoclaves are also known as steam sterilizers and are used to expose each item to direct steam contact at the required temperature and pressure for the specified time. They are used for healthcare or industrial applications to eliminate the protein structure of the bacteria and spores. Compatible of steam autoclaves for crisis strategy decontamination of N95 respirators is expected to propel growth of the global steam autoclave market. For instance, in October 2020, 3M, a U.S-based multinational conglomerate corporation, announced that Belimed steam autoclaves are compatible for crisis strategy decontamination of specific single-use N95 Respirators. Moreover, launch of biological indicators for steam autoclaves is also expected to aid in growth of the market. For instance, in December 2020, Steris Corporation, a U.S-based medical equipment company, launched Spordex Self-Contained Biological Indicator Ampoules to confirm sterilization of liquids in steam autoclave cycles. Emergence of Covid-19 is expected to offer lucrative growth opportunities for players in the global steam autoclave market. For instance, globally, as of 4:03pm CET, 1 March 2021, there have been 113,820,168 confirmed cases of COVID-19, including 2,527,891 deaths, reported to the World Health Organization. Moreover, high prevalence of hospital-acquired infections is also expected to aid in growth of the market. For instance, according to an observational epidemiological study of intra-abdominal infections published in December 2019, in NEJM Journal Watch, of the 2621 critically ill adults with intra-abdominal infections at 309 international centers between January and December 2016, 32% were community-acquired, while 68% were hospital-acquired. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/03/emergence-of-covid-19-and-lunch-of-new.html

Primary biliary cholangitis, also known as primary biliary cirrhosis, is an autoimmune disease of the liver. The auto-immune disorder can have a number of symptoms such as abdominal pain, fever, nausea, vomiting, abdominal bloating, diarrhea, liver tenderness or enlargement, jaundice, and ascites. In most of these symptoms, the patient may be experiencing inflammation at an early stage of the illness, although in some cases, symptoms do not appear until the disease has advanced to a more serious state. A definitive diagnosis can only be made by performing blood tests and ultrasound studies in order to determine the progression of the illness and its effects on the body. At an early stage, most patients who experience mild to moderate symptoms of primary biliary cholangitis exhibit no symptoms, whereas in some cases, symptoms manifest very quickly and rapidly worsen. In both conditions, the majority of affected individuals undergo treatment that is aimed at relieving pain and treating any complications that might occur. High prevalence of primary biliary cholangitis is expected to propel growth of the primary biliary cirrhosis drugs market. For instance, according to the study, 'Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis', published in Hepatology International in September 2019, the overall prevalence of primary biliary cholangitis was 118.75 cases per million in the Asia Pacific region, with the high, medium and low prevalence being in Japan and China (191.18 cases per million), New Zealand (99.16 cases per million) and South Korea and Australia (39.09 cases per million), respectively. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/01/high-prevalence-of-primary-biliary.html